Drug
Spn 812
Spn 812: highest development phase Post-Market, developed by Supernus Pharmaceuticals. 10 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Supernus Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| SPN-812 (600mg, QD) NCT06259331 | Post-Market | Healthy Lactating Women |
| SPN-812 NCT06185985 | Post-Market | Attention-Deficit/Hyperactivity Disorder |
| 100mg SPN-812 NCT04781140 | Post-Market | Attention-Deficit/Hyperactivity Disorder |
| 100mg SPN-812 NCT03247530 | Phase 3 | ADHD |
| 200 mg SPN-812 NCT04016792 | Phase 3 | ADHD |
| SPN-812 NCT04143217 | Phase 3 | Attention-Deficit/Hyperactivity Disorder |
| 200mg SPN-812 NCT03247517 | Phase 3 | ADHD |
| SPN-812 NCT04016779 | Phase 3 | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| SPN-812 NCT02736656 | Phase 3 | Attention-Deficit/Hyperactivity Disorder |
| 100mg SPN-812 NCT02633527 | Phase 2 | Attention-Deficit/Hyperactivity Disorder (ADHD) |
Latest
No recent events.
Follow Spn 812 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.